Cyprotex in Collaborative Research Agreement with Pfizer
October 30 2012 - 11:28AM
Dow Jones News
LONDON--Cyprotex PLC (CRX.LN), the preclinical ADME-Tox services
company, Tuesday announced a collaborative research agreement
between its wholly owned subsidiary Apredica LLC and Pfizer Inc.
(PFE).
MAIN FACTS:
-No financial details have been disclosed
-The deal extends over an eighteen month period and is split
into two stages with the second stage being dependent on certain
milestones being achieved
-The collaboration is a research-based project which the parties
aim to evaluate, further develop, and improve several of Cyprotex's
proprietary offerings in the area of predictive toxicology
-Shares closed Monday at 4.25 pence valuing the company at GBP10
million.
Write to Jana Weigand at jana.weigand@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024